Lipolysis stimulating peptides of potato protein hydrolysate effectively suppresses high-fat-diet-induced hepatocyte apoptosis and fibrosis in aging rats

ORIGINAL ARTICLE

Lipolysis stimulating peptides of potato protein hydrolysate effectively suppresses high-fat-diet-induced hepatocyte apoptosis and fibrosis in aging rats

Wen-Dee Chiang1, Chih Yang Huang2,3,4, Catherine Reena Paul2,5, Zong-Yan Lee5 and Wan-Teng Lin5*

1Department of Food Science, College of Agriculture, Tunghai University, Taichung, Taiwan; 2Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan; 3School of Chinese Medicine, China Medical University, Taichung, Taiwan; 4Department of Health and Nutrition Biotechnology, Asia University, Taichung, Taiwan; 5Department of Hospitality Management, College of Agriculture, Tunghai University, Taichung, Taiwan

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common outcomes of obesity and is characterized by the accumulation of triglycerides, increased tissue apoptosis, and fibrosis. NAFLD is more common among elderly than in younger age groups, and it causes serious hepatic complications.

Objective: In this study, alcalase treatment derived potato protein hydrolysate (APPH) with lipolysis-stimulating property has been evaluated for its efficiency to provide hepato-protection in a high-fat-diet (HFD)-fed aging rats.

Design: Twenty-four-month-old SD rats were randomly divided into six groups (n=8): aged rats fed with standard chow, HFD-induced aged obese rats, HFD with low-dose (15 mg/kg/day) APPH treatment, HFD with moderate (45 mg/kg/day) APPH treatment, HFD with high (75 mg/kg/day) APPH treatment, and HFD with probucol.

Results: APPH was found to reduce the NAFLD-related effects in rat livers induced by HFD and all of the HFD-fed rats exhibited heavier body weight than those with control chow diet. However, the HFD-induced hepatic fat accumulation was effectively attenuated in rats administered with low (15 mg/kg/day), moderate (45 mg/kg/day), and high (75 mg/kg/day) doses of APPH. APPH oral administration also suppressed the hepatic apoptosis- and fibrosis-related proteins induced by HFD.

Conclusions: Our results thus indicate that APPH potentially attenuates hepatic lipid accumulation and anti-apoptosis and fibrosis effects in HFD-induced rats. APPH may have therapeutic potential in the amelioration of NAFLD liver damage.

Keywords: apoptosis; fibrosis; high fat diet; lipolysis stimulating protein hydrolysates; obesity; APPH

Citation: Food & Nutrition Research 2016, 60: 31417 - http://dx.doi.org/10.3402/fnr.v60.31417

Copyright: © 2016 Wen-Dee Chiang et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.

Received: 24 February 2016; Revised: 5 May 2016; Accepted: 5 May 2016; Published: 12 July 2016

Competing interests and funding: The authors declare no conflict of financial interest. This Research was financially supported by a grant from the Ministry of Science and Technology of Taiwan (MOST103-2410-H-029-037 and MOST104-2410-H-029-033-MY2).

*Correspondence to: Wan-Teng Lin, Department of Hospitality Management, College of Agriculture, Tunghai University, No.1727, Sec.4, Taiwan Boulevard, Situn District, Taichung City 40704, Taiwan. Email: 040770@thu.edu.tw

 

Aging is a biological process characterized by a progressive decrease in physiological capacity and increases in age-related diseases, and the process of aging is frequently associated with progressive insulin resistance and associated decline in blood sugar regulation, arising from deteriorated control of glucose production and triglyceride secretion in the liver (1). Aging therefore increases the occurrence of metabolic disorders such as dyslipidemia and hyperinsulinemia (24). Non-alcoholic fatty liver disease (NAFLD) is a common metabolic syndrome that progresses into chronic liver disease in obese adults (5, 6). Hypernutrition or insulin resistance potentially causes imbalance in the uptake and removal of lipids in the liver, leading to excess accumulation of hepatic triglycerides (7). NAFLD occurs more often in the middle-aged and in the elderly as the risk factors for NAFLD increases with aging (8). Hepatic apoptosis is one of the reasons for NAFLD-induced liver injury (9, 10). A higher incidence of apoptosis also leads to hepatic fibrosis. Therefore, inhibition of hepatic apoptosis is a potential approach in treating NAFLD. As there are no drugs so far that effectively treat NAFLD, diet control and diet-related treatment become more crucial in preventing NAFLD (7).

Potato (Solanum tuberosum L.) is an important food crop and a major source of high-quality proteins, minerals, and antioxidants, including vitamin C (11). Recent reports highlight the efficiency of the potato as an effective functional food with various health-promoting benefits such as protection from degenerative diseases, cancer, heart disease, and hypertension (11). Enzymatic hydrolysis of dietary proteins produces potential bioactive peptides with altered molecular size, hydrophobicity, and polar groups of peptides (12). Alcalase treatment–derived potato protein hydrolysate (APPH) with lipolysis-stimulating property was found to have the potential to act as an efficient anti-obesity diet ingredient (1315). Recent in vitro studies on the stability of APPH against gastric proteases also show that APPH is highly resistant to proteolytic digestion (15).

In this study, we investigated the effect of APPH on fatty liver–associated hepatic apoptosis and fibrosis in aged obese rats. Twenty-four-month-old male SD rats that were fed with HFD for 60 days (HFD group) were found to develop symptoms of NAFLD with hepatic apoptosis and fibrosis. However, HFD-fed rats treated with different doses of APPH for the final 30 days showed a significant reduction in HFD-related apoptosis and fibrosis. The administration of APPH also protected the liver by reducing the accumulation of lipid droplets and regulating the level of apoptosis- and fibrosis-related events. APPH administration can therefore be considered as a potential therapeutic agent to ameliorate aging-associated NAFLD effects.

Materials and methods

APPH preparation

APPH was prepared, purified, and characterized as reported previously; the characteristics were consistent with the composition of APPH mentioned in earlier reports (13). Briefly, a reaction mixture containing 2.5% commercially purchased potato protein (Han-Sient Corporation, Taipei, Taiwan) and 1% alcalase enzyme (Nono Nodisk A/S, Bagsvaerd, Denmark) were used to produce potato protein hydrolysate (~81% protein) by subjecting it to alcalase enzyme hydrolysis for 2 h. The molecular size of the resultant APPH was determined using different membrane cut-off filters. It was confirmed, as in the previous report, that 5% of the content was >6,000 Da, 40% was between 1,000 and 6,000 Da, and 55% was <1,000 Da size. The hydrolysate was vacuum-dried and stored for future use. The degree of hydrolysis of the product was more than 9.5% and the hydrolysate was fractionated by reverse phase HPLC; characterized according to the methods reported previously (13, 16) by MS/MS/TIC and by analyzing the data with TurboSequest (Thermo Fisher Scientific, MA, USA) against protein database (UniProt, Solanum tuberosum) and the results revealed the presence of peptides with patatin sequences (Fig. 1).

Fig 1

Fig. 1.   Characterization of lipolysis stimulating APPH. (a) MS/MS/TIC chromatogram for APPH. (b) Ion series for chosen peptides from the MS/MS/TIC chromatogram showing sequence homogeneity with patatin.

Animal experiments

This study was conducted according to the IACUC-100-12 protocol after appropriate ethical approval from the Institutional Animal Care and Use Committee (IACUC) of the China Medical University, Taiwan. Five-week-old male SD rats were housed in cages maintained at 24±2°C and 55±10% humidity with a 12-h light cycle, and the rats were allowed to feed on normal laboratory chow for 22 months. The rats were randomly divided into six groups (n=8): aged rats fed with standard chow, aged rats fed with HFD, aged rats with HFD and low-dose (15 mg/kg/day) APPH treatment, aged rats with HFD and moderate dose (45 mg/kg/day) APPH treatment, aged rats with HFD and high-dose (75 mg/kg/day) APPH treatment, and aged rats with HFD and probucol. The animals were fed with a standard laboratory diet (PMI Nutrition International, Brentwood, MO, USA) and provided with reverse osmosis–treated water ad libitum. In the next 8 weeks, obesity was induced by giving HFD (58Y1, LabDiet, Missouri, USA) containing 60% of energy as fat. The treatment was administrated orally using non-flexible needless feeding gavage simultaneously during the next 30 days of HFD feeding course. The probucol treatment group rats were fed with high fat diet and probucol (500 mg/kg/day).

Hematoxylin and eosin staining

The livers were excised; soaked in formalin; dehydrated by passing through 100, 95, and 75% alcohol sequentially and then embedded in paraffin wax. The embedded tissue blocks were cut into 0.2-µm-thick sections and de-paraffinized by soaking in xylene. The slices were stained using hematoxylin and eosin (H&E) and rinsed with water. Photomicrographs were obtained using Zeiss Axiophot microscopes (Carl Zeiss Microscopy, Thornwood, NY, USA).

Terminal deoxynucleotide transferase-mediated dUTP Nick End Labeling (TUNEL)

The tissue sections were incubated with proteinase K, washed in phosphate-buffered saline, incubated with permeabilization solution, blocking buffer, and then washed two times with PBS. The sections were stained with terminal deoxynucleotidyl transferase and fluorescein isothiocyanate- dUTP (Roche Applied Science, Indianapolis, IN, USA) for 60 min at 37°C in order to detect the number of apoptotic nuclei. The tissue sections were also stained with 0.1 µg/mL 4’,6-diamidino-2-phenylindole (DAPI) for 5 min, and the nuclei were detected by UV light microscopy at 454 nm. Photomicrographs were obtained using a Zeiss Axiophot microscope. All counts were performed by at least three independent individuals in a blinded manner.

Masson’s trichrome staining

Liver tissues were fixed in formalin, embedded in paraffin, and sectioned. Slides were hydrated through a series of graded alcohols (100, 95, and 75%), for 15 min each. The slides were then stained with Masson’s trichrome dye. And photomicrographs were obtained using the Zeiss Axiophot microscopes.

Tissue protein extraction and western blotting

Proteins were obtained by homogenizing the liver tissue in lysis buffer (100 mg/mL). The homogenates were placed on ice and then centrifuged at 12,000 g for 40 min. The supernatants were collected and stored at −80°C for further experiments. The extract protein concentration was determined using the Lowry protein assay method. Protein samples were separated in a 12% SDS polyacrylamide gel electrophoresis (SDS-PAGE) using 75 V of constant power supply. Proteins were then transferred to PVDF (GE Healthcare Life Sciences, Pittsburgh, PA, USA) membranes using 50 V current for 3 h. The membranes were incubated in 3% bovine serum albumin (BSA) in TBS buffer and the primary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were added onto the membranes for conjugation with specific proteins. Horseradish peroxidase–labelled secondary antibodies were used for detection, and pictures were finally taken with Fujifilm LAS-3000 (GE Healthcare Life Sciences).

Statistical analysis

The results shown are the means±SD of three independent experiments. Statistical analysis was performed by one-way analysis of variants. For paired samples, the Student’s t test was used.

Results

APPH administration alleviated HFD-induced effects

The HFD intake induced several notable changes in the test rats. The rats fed with HFD showed significant increase in body weight compared to the control rats. Although some reduction in body weight was observed, the effect of APPH and probucol on the HFD induced increase in body weight was not statistically significant (Fig. 2). Massive fat accumulation in the livers of rats fed with HFD was also observed from H&E-stained liver sections (Fig. 3). However, APPH treatment effectively reduced the fat accumulation in the liver tissue. Moderate and high dose of APPH were comparatively more effective in attenuating the fat accumulation than the probucol treatment group.

Fig 2

Fig. 2.   Effect of APPH on total body weight changes. The changes in body weight (g) were measured in the controls and in the treatment groups were determined. The results represent mean±SD (n=8). *P<0.05, when compared with control group (one-way ANOVA analysis).

Fig 3

Fig. 3.   Hematoxylin and eosin (H&E) staining of tissue sections showing the liver tissue architecture and lipid droplets. Histopathological analysis of hepatic sections of control rats, high-fat-diet-fed rats, and the treatment group rats was performed. Magnification 400x.

APPH administration supresses apoptosis

TUNEL and DAPI staining of the liver sections showed more number of TUNEL positive cells in HFD rat groups indicating a hepatotoxic effect caused by HFD feeding. However, treatment with low, moderate, and high levels of APPH supressed the number of apoptosis nuclei in a dose-dependent manner (Fig. 4).

Fig 4

Fig. 4.   Effect of APPH on cellular apoptosis. DAPI and TUNEL stained liver sections show the degree of apoptosis in control rats, high-fat-diet-fed rats, and the treatment group rats. Magnification 400x. ***P<0.001, when compared with control group and ###P<0.001 when compared with HFD group.

APPH administration regulates apoptosis- and survival-related proteins

The protein expression in the HFD-fed rat livers, when analyzed by western blotting, revealed that the incidence of fatty liver in rats is correlated with suppression in the levels of activated phosphatidylinositol 3-kinase (p-PI3K) and serine–threonine kinase (p-Akt) and elevation in pro-apoptotic protein levels such as Fas receptor (Fas), Fas-Associated protein with Death Domain (FADD), Bcl-2 associated X protein (Bax), and activated caspase 3. However, in the rat groups administered with low, moderate, and high levels of APPH, the levels of survival proteins were elevated (Fig. 5) and the levels of apoptosis proteins were suppressed (Fig. 6).

Fig 5

Fig. 5.   Effect of APPH on survival proteins. The cell survival protein levels such as p-PI3K and p-Akt in the 24-month-old control rats, high-fat-diet-fed rats, and the treatment group rats. **P<0.01 and ***P<0.001, when compared with control group #P<0.05, ##P<0.01 and ###P<0.001 when compared with the HFD group.

Fig 6

Fig. 6.   Effect of APPH on apoptosis marker proteins. The levels of apoptosis protein such as Fas, FADD, Bax, and caspase 3 in the 24-month-old control rats, high-fat diet-fed rats, and the treatment group rats. ***P<0.001, when compared with control group, ##P<0.01 and ###P<0.001 when compared with HFD group.

Effect of APPH on liver fibrosis

Masson’s trichrome staining of LV tissue sections revealed that HFD in aging rats induced liver fibrosis (Fig. 7). Tissue sections showed prominent blue staining in the HFD-fed rat liver sections. However, treatment with APPH effectively reduced the fibrosis effects induced by HFD. The results show that APPH has more potential than probucol to inhibit HFD associated liver fibrosis in hamster livers.

Fig 7

Fig. 7.   Effect of APPH on fibrosis. Masson’s trichrome staining in liver tissue sections from 24-month-old control rats, high-fat-diet-fed rats, and the treatment group rats. Magnification 400x.

Discussion

Age-related disorders are widespread throughout the world and are the leading cause of death in developed countries. The deterioration of organ structure and function during aging is associated with oxidative stress, genetic instability, and the disruption of homeostatic pathways, resulting in metabolic syndromes such as obesity, insulin resistance, impaired glucose tolerance or overt diabetes, hypertension, dyslipidemia, and cardiovascular complications (16). Diabetes is also recognized to accelerate aging, but the mechanisms linking diabetes and aging are poorly understood (17).

Obesity is a major cause of insulin resistance and is linked to several common diseases such as type two diabetes, cardiovascular disease, NAFLD, and various cancers (1820). The HFD-fed rats used in our experiments displayed liver apoptosis and fibrosis symptoms as determined from their liver histology. APPH effectively reduced the liver fat accumulation; however, this change would have caused an increase in fat accumulation elsewhere in the form of visceral or the adipose fat. Therefore, changes in the liver lipid mass were not reflected on the total body weight differences post APPH treatment. The potato proteins have been classified tentatively into three classes: patatin family (41 kDa; ≈40% of total soluble protein), protease inhibitors (5–25 kDa; ≈50% of total soluble protein), and others (21). Patatin exhibits a known lipid acyl hydrolase (LAH) activity (21). APPH contains fragments of lipolysis stimulating peptides such as patatin that has proven anti-obesity effect in rodents. APPH administration is known to confer cardiac protection and improve heart function against HFD-induced effects by attenuating apoptosis and by improving cardiomyocyte survival mechanism (13). In aging rats, APPH administration efficiently reduces serum triacylglycerol and total cholesterol (TC) levels and provides cardio protection to the HFD-fed ailing rats (14). Our present study reveals the effect of APPH in preventing HFD-induced fatty liver and liver fibrosis in aging rats.

The causes of chronic liver diseases are known to be multifactorial, involving obesity, insulin resistance, inflammation, and oxidative stress. Targeting these pathways is considered a potential treatment approach but the strategy has either shown limited efficacy or an unfavorable safety profile (22). Increased hepatocyte apoptosis is a prominent feature of liver diseases leading to liver damage, severe inflammation, and fibrosis. Inflammatory cytokines from hepatocytes in response to liver injury may lead to NAFLD (23, 24). Two major cellular pathways are attributed to the induction and progression of apoptosis in response to different types of stimuli (25). The intrinsic pathway involves the disruption of mitochondrial membrane potential and release of cytochrome c, thereby triggering caspase 9. The extrinsic pathway involves activation of death receptors such as the Fas receptor, recruitment of the adaptor molecule FADD, and activation of caspase 8 (26). The members of the Bcl-2 family of proteins-Bcl-2 and Bax, that are, respectively, anti-apoptotic and pro-apoptotic factors, are crucial markers of the events in apoptosis (26). The results indicate that the extrinsic apoptosis pathway proteins that were elevated in HFD-fed rats were regulated when treated with APPH. The APPH also up-regulated Bax in the livers of HFD-fed rats. Therefore, our results indicate that HFD increases apoptosis in rat livers but is regulated when treated with APPH.

Obesity is known to be associated with PI3K/AKT pathway deregulation (27). The IGF1R mediated activation of PI3K and AKT prompts immune cell activation by regulating key inflammatory cytokines (28, 29). APPH treatment has also shown to compensatively enhance IGF1R-PI3K-Akt signaling to improve the cardiomyocyte viability in aging rat hearts (14). In this study, APPH administration increased the levels of PI3K and AKT in HFD-fed rats, indicating improvements in the hepatocyte survival condition. Further, as a consequence of apoptosis associated liver injury, hepatic stellate cells are known to migrate to the apoptosis site to engulf apoptotic bodies. In this process, hepatic stellates are activated to promote the deposition of extracellular matrix and scar formation in the liver (30).

Probucol is a potent antioxidative drug that has been used for the prevention and treatment of atherosclerotic cardiovascular diseases due to its lipid-lowering effects. Probucol decreases serum LDL-C by 10–20% and enhances the excretion of cholesterol into bile (31). Probucol has been known to be effective in attenuating biochemical and histological changes associated with NASH. Probucol treatment normalizes the serum aminotransferase levels and improves hepatic inflammation and fibrosis (32, 33). However, probucol also reduces serum HDL-cholesterol, thereby restricting its therapeutic usage (34). The APPH has shown superior activity compared to probucol and therefore APPH is potentially a valuable alternative to probucol.

In this study, the effect of APPH to attenuate HFD-related apoptosis and fibrosis was determined in HFD-fed aging rat livers. HFD induced changes in the rat bodyweight and expression levels of cellular apoptosis and fibrosis proteins; however, the modulations were found to be regulated when treated with APPH. Therefore, low, moderate, and high concentrations of APPH can potentially rescue rat livers from the effects of HFD.

References

  1. Lee J, Cho JY, Kim WK. Anti-inflammation effect of exercise and Korean red ginseng in aging model rats with diet-induced atherosclerosis. Nutr Res Pract 2014; 8(3): 284–91. PubMed Abstract | PubMed Central Full Text | Publisher Full Text
  2. Elahi D, Muller DC, Egan JM, Andres R, Veldhuist J, Meneilly GS. Glucose tolerance, glucose utilization and insulin secretion in ageing. Novartis Found Symp 2002; 242: 222–42; discussion 42–6.PubMed Abstract
  3. Buettner R, Scholmerich J, Bollheimer LC. High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity (Silver Spring) 2007; 15(4): 798–808. PubMed Abstract | Publisher Full Text
  4. Bravo E, Rivabene R, Bruscalupi G, Calcabrini A, Arancia G, Cantafora A. Age-related changes in lipid secretion of perfused livers from male Wistar rats donors. J Biochem 1996; 119(2): 240–5. PubMed Abstract | Publisher Full Text
  5. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther 2012; 36(9): 815–23. PubMed Abstract
  6. Bogdanova K, Poczatkova H, Uherkova L, Riegrova D, Rypka M, Feher J, et al. Non-alcoholic fatty liver disease (NAFLD) – a novel common aspect of the metabolic syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006; 150(1): 101–4. PubMed Abstract | Publisher Full Text
  7. Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol 2013; 48(4): 434–41. PubMed Abstract | PubMed Central Full Text | Publisher Full Text
  8. Bertolotti M, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri S, et al. Nonalcoholic fatty liver disease and aging: epidemiology to management. World J Gastroenterol 2014; 20(39): 14185–204. PubMed Abstract | PubMed Central Full Text | Publisher Full Text
  9. Jiang Y, Zhao MY, An W. Increased hepatic apoptosis in high-fat diet-induced NASH in rats may be associated with downregulation of hepatic stimulator substance. J Mol Med-Jmm 2011; 89(12): 1207–17. Publisher Full Text
  10. Xiao J, Guo R, Fung ML, Liong EC, Chang RCC, Ching YP, et al. Garlic-derived S-allylmercaptocysteine ameliorates nonalcoholic fatty liver disease in a rat model through inhibition of apoptosis and enhancing autophagy. Evidence-Based Complement Alternat Med 2013; 2013: 642920.
  11. Valinas MA, Lanteri ML, ten Have A, Andreu AB. Chlorogenic acid biosynthesis appears linked with suberin production in potato tuber (Solanum tuberosum). J Agric Food Chem 2015; 63(19): 4902–13. PubMed Abstract | Publisher Full Text
  12. Ambigaipalan P, Shahidi F. Antioxidant potential of date (Phoenix dactylifera L.) seed protein hydrolysates and carnosine in food and biological systems. J Agric Food Chem 2015; 63(3): 864–71. PubMed Abstract | Publisher Full Text
  13. Huang CY, Chiang WD, Pai PY, Lin WT. Potato protein hydrolysate attenuates high fat diet-induced cardiac apoptosis through SIRT1/PGC-1a/Akt signalling. J Funct Foods 2015; 12: 389–98. Publisher Full Text
  14. Hu WS, Ting WJ, Chiang WD, Pai P, Yeh YL, Chang CH, et al. The heart protection effect of alcalase potato protein hydrolysate is through IGF1R-PI3K-Akt compensatory reactivation in aging rats on high fat diets. Int J Mol Sci 2015; 16(5): 10158–72. PubMed Abstract | PubMed Central Full Text | Publisher Full Text
  15. Lin WT, Lee KI, Hong MC, Chiang WD. Production of potato protein hydrolysates with 2 lipolysis-stimulating activity and study of 3 their possible regulation mechanism. Taiwanese J Agric Chem Food Sci 2016; 54(2): 53–63.
  16. Tsou MJ, Kao FJ, Lu HC, Kao HC, Chiang WD. Purification and identification of lipolysis-stimulating peptides derived from enzymatic hydrolysis of soy protein. Food Chem 2013; 138(2–3): 1454–60. PubMed Abstract | Publisher Full Text
  17. Ahima RS. Connecting obesity, aging and diabetes. Nature Med 2009; 15(9): 996–7. PubMed Abstract | Publisher Full Text
  18. Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010; 69(2): 211–20. PubMed Abstract | Publisher Full Text
  19. Huang C-Y, Lee S-D. Possible pathophysiology of heart failure in obesity: cardiac apoptosis. Bio Med 2012; 2(1): 36–40.
  20. Sundaram S, Johnson AR, Makowski L. Obesity, metabolism and the microenvironment: links to cancer. J Carcinog 2013; 12: 19. PubMed Abstract | PubMed Central Full Text | Publisher Full Text
  21. van Koningsveld GA, Walstra P, Voragen AG, Kuijpers IJ, van Boekel MA, Gruppen H. Effects of protein composition and enzymatic activity on formation and properties of potato protein stabilized emulsions. J Agric Food Chem 2006; 54(17): 6419–27. PubMed Abstract | Publisher Full Text
  22. Bouziana SD, Tziomalos K. Inhibition of apoptosis in the management of nonalcoholic fatty liver disease. World J Gastrointest Pharmacol Ther 2013; 4(1): 4–8. PubMed Abstract | PubMed Central Full Text | Publisher Full Text
  23. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49(1): 306–17. PubMed Abstract | PubMed Central Full Text | Publisher Full Text
  24. Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res 2012; 2012: 716404. PubMed Abstract | Publisher Full Text
  25. Green DR. Apoptosis – death deceiver. Nature 1998; 396(6712): 629–30. PubMed Abstract | Publisher Full Text
  26. Park MT, Kang JA, Choi JA, Kang CM, Kim TH, Bae S, et al. Phytosphingosine induces apoptotic cell death via caspase 8 activation and Bax translocation in human cancer cells. Clin Canc Res 2003; 9(2): 878–85.
  27. Matsuda S, Kobayashi M, Kitagishi Y. Roles for PI3K/AKT/PTEN Pathway in cell signaling of nonalcoholic fatty liver disease. ISRN Endocrinol 2013; 2013: 472432. PubMed Abstract | PubMed Central Full Text | Publisher Full Text
  28. Ou HC, Tzang BS, Chang MH, Liu CT, Liu HW, Lii CK, et al. Cardiac contractile dysfunction and apoptosis in streptozotocin-induced diabetic rats are ameliorated by garlic oil supplementation. J Agric Food Chem 2010; 58(19): 10347–55. PubMed Abstract | Publisher Full Text
  29. Goto M, Iwase A, Harata T, Takigawa S, Suzuki K, Manabe S, et al. IGF1-induced AKT phosphorylation and cell proliferation are suppressed with the increase in PTEN during luteinization in human granulosa cells. Reproduction 2009; 137(5): 835–42. PubMed Abstract | Publisher Full Text
  30. Chakraborty JB, Oakley F, Walsh MJ. Mechanisms and biomarkers of apoptosis in liver disease and fibrosis. Int J Hepatol 2012; 2012: 648915. PubMed Abstract | PubMed Central Full Text | Publisher Full Text
  31. Tawara K, Tomikawa M, Abiko Y. Mode of action of probucol in reducing serum cholesterol in mice. Jpn J Pharmacol 1986; 40(1): 123–33. PubMed Abstract | Publisher Full Text
  32. Merat S, Malekzadeh R, Sohrabi MR, Hormazdi M, Naserimoghadam S, Mikaeli J, et al. Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study. J Clin Gastroenterol 2003; 36(3): 266–8. PubMed Abstract | Publisher Full Text
  33. Tokushige K, Hashimoto E, Yatsuji S, Taniai M, Shiratori K. Combined pantethine and probucol therapy for Japanese patients with non-alcoholic steatohepatitis. Hepatol Res 2007; 37(10): 872–7. PubMed Abstract | Publisher Full Text
  34. Yamashita S, Masuda D, Matsuzawa Y. Did we abandon probucol too soon? Curr Opin Lipidol 2015; 26(4): 304–16. PubMed Abstract | Publisher Full Text

Footnote

These authors contributed equally to this work.

About The Authors

Wen-Dee Chiang

Taiwan, Province of China

Chih-Yang Huang

Taiwan, Province of China

Catherine Reena Paul

Taiwan, Province of China

Zong-Yan Lee

Taiwan, Province of China

Wan-Teng Lin

Taiwan, Province of China

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Related Content